Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Lexicon Pharmaceuticals ( (LXRX) ) has shared an update.
On July 3, 2025, Lexicon Pharmaceuticals received a letter from Nasdaq indicating eligibility for an additional 180-day period to regain compliance with the minimum $1 bid price requirement for its common stock. The company applied to transfer its stock from the Nasdaq Global Select Market to the Nasdaq Capital Market, which was approved, and the transfer will occur on July 7, 2025. This move allows Lexicon Pharmaceuticals more time to meet the bid price requirement, with plans to potentially implement a reverse stock split if necessary.
The most recent analyst rating on (LXRX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Lexicon Pharmaceuticals stock, see the LXRX Stock Forecast page.
Spark’s Take on LXRX Stock
According to Spark, TipRanks’ AI Analyst, LXRX is a Neutral.
Lexicon Pharmaceuticals receives an overall score of 60, driven by positive technical indicators and a strong earnings call highlighting strategic partnerships and reduced losses. However, financial performance remains weak with ongoing profitability challenges and a negative valuation score, reflecting the need for continued financial improvement.
To see Spark’s full report on LXRX stock, click here.
More about Lexicon Pharmaceuticals
Average Trading Volume: 5,626,728
Technical Sentiment Signal: Sell
Current Market Cap: $321.1M
Find detailed analytics on LXRX stock on TipRanks’ Stock Analysis page.